Feldman v. Lederle Laboratories

Citation97 N.J. 429,479 A.2d 374
Parties, 14 Envtl. L. Rep. 20,855, 39 UCC Rep.Serv. 866 Carol Ann FELDMAN, Plaintiff-Appellant, v. LEDERLE LABORATORIES, a corporation, and American Cyanamid Company, a corporation, Defendants-Respondents.
Decision Date30 July 1984
CourtUnited States State Supreme Court (New Jersey)

James I. Peck, IV, West Orange, for plaintiff-appellant.

James L. Melhuish, Livingston, for defendants-respondents (Morgan, Melhuish, Monaghan, Arvidson, Abrutyn & Lisowski, Livingston attorneys; James L. Melhuish and Bernard A. Leroe, Livingston, of counsel; James L. Melhuish and Kevin E. Wolff, Livingston, on the briefs).

Arthur Ian Miltz, Livingston, for amicus curiae The N.J. Affiliate of the Ass'n of the Trial Lawyers of America (Kronisch & Schkeeper, Livingston, attorneys).

John L. McGoldrick, Newark, for amici curiae (McCarter & English, Newark, attorneys for Pharmaceutical Mfrs. Ass'n and Eli Lilly and Co.; Lum, Biunno & Tompkins, Newark, attorneys for Abbott Laboratories; Braff, Litvak, Ertag, Wortmann & Harris, Livingston, attorneys for Burroughs Wellcome Co.; Shanley & Fisher, Newark, attorneys for Merck & Co., Inc.; Porzio, Bromberg & Newman, Morristown, attorneys for Pfizer Inc. and Warner-Lambert Co.; Kuttner & Toner, Roseland, attorneys for Schering-Plough Corp.; Sills, Beck, Cummis, Zuckerman, Radin & Tischman, Newark, attorneys for E.R. Squibb & Sons, Inc.; Lamb, Hutchinson, Chappell, Ryan & Hartung, Jersey City, attorneys for The Upjohn Co.; John L. McGoldrick, Keith E. Lynott, David R. Kott, John F. Brenner, and Gordon M. Chapman, Newark, on the brief).

Barry M. Epstein, Newark, submitted a separate brief on behalf of amicus curiae E.R. Squibb & Sons, Inc. (Sills, Beck, Cummis, Zuckerman, Radin & Tischman, Newark, attorneys; Marc S. Klein, Newark, on the brief).

The opinion of the Court was delivered by

SCHREIBER, J.

In this case defendants and amici drug manufacturers argued that the doctrine of strict products liability should not apply to prescription drugs. We hold otherwise and conclude that drug manufacturers have a duty to warn of dangers of which they know or should have known on the basis of reasonably obtainable or available knowledge.

Plaintiff, Carol Ann Feldman, has gray teeth as a result of taking a tetracyline drug, Declomycin. Plaintiff's father, a pharmacist and a medical doctor, prescribed and administered the drug to her when she was an infant to control upper respiratory and other secondary types of infections. Since Dr. Feldman claimed that he had administered Declomycin, suit was instituted against defendant, Lederle Laboratories, 1 which manufactured and marketed Declomycin. 2 The action was presented to the jury on the theory that the defendant was strictly liable, not because the drug was ineffective as an antibiotic, but because defendant had failed to warn physicians of the drug's side effect, tooth discoloration.

Defendant contended that the plaintiff had not proven that the drug she received was Declomycin. Rather, according to the defendant, the plaintiff could have ingested one of several other tetracycline drugs, any of which could have caused the discoloration. Further, defendant argued that it had complied with the state of the art in its warning literature. It had not warned of possible tooth discoloration because, the defendant claimed, the possibility of that side effect was not known at the time its literature was disseminated.

The jury found for the defendant. The Appellate Division affirmed in an unreported opinion. Plaintiff petitioned for certification and we summarily remanded the cause to the Appellate Division to reconsider in light of Beshada v. Johns-Manville Prods. Corp., 90 N.J. 191, 447 A.2d 539 (1982), which was decided after the Appellate Division decision. 91 N.J. 266, 450 A.2d 579 (1982). The Appellate Division reaffirmed the judgment for the defendant, holding that prescription drugs are a special category of products and that drug manufacturers would not be strictly liable for failing to warn of a side effect that was unknown when the drug was sold. 189 N.J.Super. 424, 460 A.2d 203 (1983). We granted plaintiff's petition for certification. 94 N.J. 594, 468 A.2d 230 (1983). We permitted the following amici to participate in the proceeding before us: ATLA-NJ, The New Jersey Affiliate of the Association of Trial Lawyers of America; the Pharmaceutical Manufacturers Association; and numerous drug manufacturers.

I

Most facts are undisputed, although there are some sharply disputed conclusions and opinions by the respective experts. Tetracyclines are a group of antibiotics that was first introduced in 1948. They were produced by different drug manufacturers that marketed the drugs under various trade names.

Defendant first marketed Declomycin in 1959. The Physicians' Desk Reference (PDR), a book used by doctors to determine effects of drugs, contains data furnished by drug manufacturers about drugs, their compositions, usages, and reactions. The 1959 PDR entry for Declomycin stated that it had a greater antibiotic potency that made it possible to achieve therapeutic activity with less weight of antibiotic; it had a reduced renal clearance rate that produced a prolongation of the antibacterial levels in the body; and it was therapeutically equally effective as other tetracyclines in infections caused by organisms sensitive to the tetracyclines. The PDR is produced annually. Until the 1965 or 1966 edition, the PDR did not mention that tooth discoloration was a possible side effect of Declomycin. Since 1965 or 1966 the PDR has stated that the drug, when administered to infants and children, could cause tooth discoloration that would be permanent if the drug were given during the developmental stage of the permanent teeth.

Plaintiff, Carol Ann Feldman, was born on February 8, 1960. Her father, Dr. Harold Feldman, asserted that he prescribed Declomycin for her approximately seven or more times from September or October, 1960, when she was eight or nine months old, until the end of 1963. She was given this drug to prevent secondary infections when she had different childhood diseases. In his words, "[i]t was a very effective drug for what I was using it for." He had been introduced to the drug by a medical representative employed by the defendant. The representative gave him a number of samples to be distributed to patients.

Plaintiff's baby teeth were discolored gray-brown. Her permanent teeth were more deeply discolored, being primarily gray. The parties agreed that this discoloration had resulted from use of a tetracycline, although they disputed whether Declomycin was the particular tetracycline involved. In this respect defendant relied in large part upon plaintiff's testimony that her parents had told her the discoloration had been caused by "tetracycline" and on testimony that plaintiff's mother had stated to plaintiff's expert that her daughter had taken "tetracycline."

The respective experts, Dr. Bonda for the plaintiff and Dr. Guggenheimer for the defendant, agreed that scientific literature existed by 1960 that referred to tooth staining being caused by tetracycline. Dr. Bonda specifically mentioned a 1956 article by Dr. Andre reciting that tetracycline accumulated in mineralized portions of growing bones and teeth of mice; an article by Dr. Milch in the July, 1957 Journal of the National Cancer Institute reporting that laboratory animals had yellow fluorescents in bones, including teeth, following dosages of tetracycline; a second article by Dr. Milch in the July, 1958 issue of the Journal of Bone and Joint Surgery again describing fluorescents in the bones and incisor teeth of rodents that had been fed tetracycline; a 1959 article by Dr. Swackman noting that of 50 children with cystic fibrosis who had received massive doses of tetracycline, 40 had dark tooth staining; a 1960 letter from Dr. Sigrelli, a Columbia University professor, to the Pediatric Journal observing that patients with cystic fibrosis of the pancreas who had received tetracyclines as an antibiotic suffered severe discoloration of their teeth, possibly as a result of their tetracycline use; a May, 1961 article by Dr. Sigrelli in the New Jersey/New York State Dental Journal containing the same information; and an essay by Dr. Bevlander on "The Effect of the Administration of Tetracycline on the Development of Teeth" in the October, 1961 issue of the Journal of Dental Research reflecting the adverse effect of tetracycline on developing teeth in young laboratory animals. Dr. Bonda concluded the defendant should have begun to investigate the possible effects of all forms of tetracycline on teeth no later than 1956, when the Andre article appeared.

Defendant's expert, Dr. Guggenheimer, on the other hand, noted that before 1962 the literature on tooth discoloration concerned only patients with cystic fibrosis who had been receiving massive doses of tetracyclines. He pointed out that Dr. Milch's papers described only fluorescents, not tooth staining. He testified that Declomycin did not become available until 1959 and that it would take 2 1/2 years for permanent teeth developing in 1959 to erupt. The completion of accurate controlled studies of multiple well-documented cases would have been the only way one could really know whether Declomycin caused tooth discoloration in permanent teeth. Dr. Guggenheimer's testimony is unclear as to whether a correlation between tetracycline and tooth discoloration had been established in 1962. One reading of his testimony indicates that such a correlation was not known to exist and that only by hindsight could that conclusion be drawn. It is also possible to interpret his opinion to be that such correlation had been established in 1962. In any event it is significant that Dr. Guggenheimer gave no opinion as to 1963.

On November 16, 1962, Dr. Swanzey, defendant's Director of Regulatory Agencies Relations,...

To continue reading

Request your trial
187 cases
  • Cipollone v. Liggett Group, Inc.
    • United States
    • U.S. District Court — District of New Jersey
    • 20 Septiembre 1984
    ...and prototypical powers. See, e.g., Ferebee v. Chevron Chemical Co., 736 F.2d 1529, 1542 (D.C.Cir.1984); Feldman v. Lederle Laboratories, 97 N.J. 429, 462, 479 A.2d 374 (Sup.Ct. of N.J. 1984).3 The presumption against preemption of these causes of action is strengthened where preemption wou......
  • Feldman v. Lederle Laboratories, a Div. of American Cyanamid Co.
    • United States
    • New Jersey Supreme Court
    • 24 Julio 1991
    ...Co. (McCarter & English, attorneys), Newark. The opinion of the Court was delivered by CLIFFORD, J. In Feldman v. Lederle Laboratories, 97 N.J. 429, 479 A.2d 374 (1984) (Feldman I), we held that under the doctrine of strict products liability, "drug manufacturers have a duty to warn of dang......
  • Whelan v. Armstrong Int'l Inc.
    • United States
    • New Jersey Supreme Court
    • 3 Junio 2020
    ...of adequate warnings about the product's inherent dangers will constitute a defect in the product itself. See Feldman v. Lederle Labs., 97 N.J. 429, 450, 479 A.2d 374 (1984) ; see also Becker, 138 N.J. at 151-52, 649 A.2d 613 ("A failure to warn, or a failure to warn properly, can constitut......
  • Bernier v. Raymark Industries, Inc.
    • United States
    • Maine Supreme Court
    • 15 Octubre 1986
    ...the manufacturer at the time of distribution is relevant in determining the applicability of strict liability. Feldman v. Lederle Labs., 97 N.J. 429, 479 A.2d 374, 388 (1984). In so doing, the court recognized that the requirement that the danger be reasonably foreseeable at the time the pr......
  • Request a trial to view additional results
5 books & journal articles
  • The Restatement (Third) of Torts: Products Liability: the ALI's cure for prescription drug design liability.
    • United States
    • Fordham Urban Law Journal Vol. 29 No. 6, August 2002
    • 1 Agosto 2002
    ...of prescription drugs immune from strict liability claims on the basis of defective design). Contra Feldman v. Lederle Labs., 479 A.2d 374, 380 (N.J. 1984) (holding manufacturers of defectively designed prescription drugs strictly liable on the basis of defective (20.) E.g., Feldman, 479 A.......
  • Renewed look at the duty to warn and affirmative defenses.
    • United States
    • Defense Counsel Journal Vol. 61 No. 2, April 1994
    • 1 Abril 1994
    ...negligence, because it is inadequacy of warning that is looked to, rather than conduct of manufacturer). (25.) Feldman v. Lederle Labs., 479 A.2d 374, 385 (N.J. 1984); Phillips v. Kimwood Mach. Co., 525 P.2d 1033, 1036 (Or. 1974). See Anderson v. Owens-Corning Fiberglass Corp., 810 P.2d 549......
  • How management of medical costs is revolutionizing the drug industry.
    • United States
    • Defense Counsel Journal Vol. 62 No. 2, April 1995
    • 1 Abril 1995
    ...unsafe and that comment k must be applied case by case. See Hill v. Searle Lab., 884 F.2d 1064 (8th Cir. 1989); Feldman v. Lederle Lab., 479 A.2d 374 (N.J. 1984). (19.)Phelps v. Sherwood Medical Indus., 836 F.2d 296, 299 (7th Cir. 1987); Willett v. Baxter Int'l Inc., 929 F.2d 1094 (5th Cir.......
  • What impact will health care reform have on vaccine and drug makers?
    • United States
    • Defense Counsel Journal Vol. 62 No. 2, April 1995
    • 1 Abril 1995
    ...injuries, the plaintiff may recover." (3.)See U.C.C. [sections] 2-315 (1987), Implied Warranty: Fitness for Particular Purpose (1987). (4.)479 A.2d 374 (N.J. (5.)751 P.2d 470 (Cal. 1988). (6.)AMERICAN LAW OF PRODUCTS LIABILITY 3D ch. 89. [sections] 2, page 8 (1987). (7.)Id. at page 15. (8.)......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT